Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Have Watchlists? Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Alexion Pharmaceuticals, Inc. Third Quarter 2020 Results. Premium. If you disable this cookie, we will not be able to save your preferences. Oct 29, 2020 at 8:00 AM EDT. Directly apply to Alexion Pharmaceuticals and find other jobs near you. Alexion Pharmaceuticals, Inc.’s (ALXN Quick Quote ALXN - Free Report) fourth-quarter adjusted earnings of $2.96 per share comfortably beat the Zacks Consensus Estimate of … All Analyst Report Morningstar • September 02, 2020 Alexion Pharmaceuticals, Inc.: Alexion’s Undervalued Rare-Disease Portfolio Will Withstand Competition; Maintaining $155 FVE Buy or Sell in volatile market - Analyst report, Corporacion America Airports Stock Forecast, Does Earnings Surprise History Hold Any Clue for, Earnings Report: Here’s what to expect from, Earnings results might Drive Its Stock Price, Empresa Distribuidora y Comercializadora Norte Sociedad Anónima, Expert Strategies Fundamental Traders Can Use To Improve Their Portfolio, Factors Likely to Have Influenced Earnings Results, Fortress Transportation and Infrastructure Investors, Fujian Blue Hat Interactive Entertainment Technology, Guangshen Railway Co. Ltd ADR Class H Stock Forecast, Hancock Jaffe Laboratories Stock Forecast, Hannon Armstrong Sustainable Infrastructure Capital, Hannon Armstrong Sustnbl Infrstr Cap Stock Forecast, Hermitage Offshore Services Stock Forecast, Hewlett Packard Enterprise Stock Forecast, Interpace Diagnostics Group Stock Forecast, InvestcorpCreditManagementBDCInc . You can find out more about which cookies we are using or switch them off in settings. Stock Forecast, IRSA Inversiones y Representaciones Sociedad Anónima, Irsa Inversiones y Rprsntcins Stock Forecast, Is it time to Buy before this week’s earning report, Ituran Location and Control Ltd. (US) Stock Forecast, Liberty Tripadvisor Holdings Inc Series A, Loma Negra Compañía Industrial Argentina Sociedad Anónima, Magyar Telekom Távközlési Nyilvánosan Müködö Részvénytársaság, may delivered a positive earnings surprise, Melco Resorts & Entertainment Stock Forecast, Metalla Royalty & Streaming Stock Forecast, Napco Security Technologies Stock Forecast, New England Realty Associates Limited Partnership, New Oriental Education & Technology Group, numbers crunched for you before earnings results, OneSmart International Edun Gr Stock Forecast, Pennsylvania Real Estate Investment Trust, Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk, Reports Strong First-Quarter Financial Results, Schultze Special Purpose Acquisition Stock Forecast, Science Applications International Stock Forecast, Second Sight Medical Products Stock Forecast, Sell or Hold? After this action, Bazarko Daniel now owns 30,883 shares of Alexion Pharmaceuticals Inc., valued at $3,795,233 using the latest closing price. Will stock surge before Earnings results. Sector (s) Healthcare. This estimate is based upon 1 Alexion Pharmaceuticals Financial Analyst salary report(s) provided by employees or estimated based upon statistical methods. According to Zacks Investment Research, based on 10 analysts’ forecasts, the consensus EPS forecast for the quarter is $2.34. Stifel 2020 Virtual Healthcare Conferenc. https://seekingalpha.com/article/4250961-alexion-investor-day-insights Historical and current end-of-day data provided by FACTSET. 90.12% of the stock of Alexion Pharmaceuticals is held by institutions. Cookie Notice (). The report will be for the fiscal Quarter ending Sep 2020. The company’s average rating score is 2.73, and is based on 14 buy ratings, 7 hold ratings, and no sell ratings. By using this site you agree to the Listen to Webcast. Duke University puts entire undergraduate population into quarantine, California’s Newsom admits pandemic mistakes but says gubernatorial recall push is not justified, Idaho ends Powerball participation amid lawmaker concern that Australia could use lottery revenue for anti-gun measures, ‘No peace’ for markets until 10-year Treasury yield hits 2%, strategist says, Wisconsin Republican Ron Johnson’s remark about feeling safe in Senate during Capitol riot labeled racist, Marco Rubio links his support for unionizing Amazon workers with an accusation of ‘wokeness’ at company, Vaccine-site volunteers frequently rewarded with early shots, What Bond Investors Should Watch This Week: Fed Decision Edition, Nancy Pelosi’s Husband Bought Up This Investment Firm’s Stock, ALXN will report 2021 earnings on 02/03/2022, ALXN will report Q1 2021 earnings on 04/29/2021. Alexion Pharmaceuticals is focused on developing effective drugs for rare diseases. Nov 17, 2020 at 10:00 AM EST. Listen to Webcast. $153.92. before and after EPS results, Ship Finance International Stock Forecast. Their average twelve-month price target is $141.65, predicting that the stock has a possible upside of 23.33%. Alexion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Earnings for Alexion Pharmaceuticals are expected to grow by 9.22% in the coming year, from $10.20 to $11.14 per share. Alexion Pharmaceuticals last posted its earnings results on July 30th, 2020. Currently, the analyst consensus on Alexion Pharmaceuticals is a Moderate Buy with an average price target of $138.00, which is a 19.6% upside from current levels. The reported EPS for the same quarter last year was $2.55. An Overall Rank of 77 means that our comprehensive methodology rates Alexion Pharm Inc above 77% of stocks. Alexion does not contact candidates via instant messaging or chat tools. 22 Wall Street analysts have issued ratings and price targets for Alexion Pharmaceuticals in the last 12 months. The biopharmaceutical company reported $3.11 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.79. ALXN updated stock price target summary. 10.7 MB. Subscriber Agreement & Terms of Use, P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. View real-time stock prices and stock quotes for a full financial overview. Alexion Reports Fourth Quarter And Full Year 2020 Results. Analyst Ratings for Alexion Pharm Inc (ALXN) provide recommendations made by outside industry experts. The company had revenue of $1.44 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Cigna (CI) Raymond James analyst John Ransom assigned a Buy rating to Cigna today and set a price target of $250.00. There are currently 7 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of “Buy.”. There are currently no items in this Watchlist. Alexion Pharmaceuticals has generated $9.74 earnings per share over the last year and currently has a price-to-earnings ratio of 30.7. Alexion compares favorably to most peers over the near-term (2019-2024) and unfavorably in long-term (2024-2029) revenue growth rates. The company’s shares closed last Thursday at $155.92, close to its 52-week high of $162.60. Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cigna (CI – Research Report), Alexion Pharmaceuticals (ALXN – Research Report) and Prestige Brand Holdings (PBH – Research Report). Alexion Pharmaceuticals has a P/B Ratio of 2.26. 26.8 MB. Alexion Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Dec 1, 2020 at 8:50 AM EST. Should you short it before the Earnings result? NYSE:CIA, NASDAQ:SLDB, NYSE:SMHI, NASDAQ:ADXS, Earnings and Growth Analysis : NASDAQ:ONCR, NYSE:PAM, NASDAQ:ASPS, NYSE:EXN, Should you short it before the Earnings result? Buy or Sell in volatile market – Analyst report Willis Towers Watson Public (NASDAQ:WLTW), Does Earnings Surprise History Hold Any Clue for NASDAQ:LMNR, NASDAQ:FNKO, NASDAQ:INOD, NYSEAMERICAN:TPHS, How Have the Numbers Shaped Up for NYSE:NL, NASDAQ:CMTL, OTCMKTS:GDPMQ, NASDAQ:CHEK, Factors Likely to Have Influenced Earnings Results NYSE:CEPU, NASDAQ:XONE, NYSE:CLPR, NASDAQ:FSTX, Earnings Report: Here’s what to expect from NYSE:RVI, NYSE:RC, NASDAQ:SYBX, NYSE:AIM, , Will stock surge before Earnings results? The report will be for the fiscal Quarter ending Sep 2020. In a report issued on May 26, Credit Suisse also assigned a Buy rating to the stock with a $142.00 price target. The reported EPS for the same quarter last year was $2.55. He kept his strong buy … Alexion Pharmaceuticals, Inc. is expected* to report earnings on 10/29/2020 before market open. This means that every time you visit this website you will need to enable or disable cookies again. 2015 Annual Report. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Alexion Pharmaceuticals has received a consensus rating of Buy. The P/E ratio of Alexion Pharmaceuticals is 30.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.13. Alexion Pharmaceuticals last posted its earnings results on July 30th, 2020. The company had revenue of $1.44 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Today is #EmployeeAppreciationDay and we are deeply grateful for the dedication and resilience of our 3,000+ employees worldwide. Create a list of the investments you want to track. Copyright © 2021 MarketWatch, Inc. All rights reserved. Visit a quote page and your recently viewed tickers will be displayed here. According to analysts’ consensus price target of $141.65, Alexion Pharmaceuticals has a forecasted upside of 23.3% from its current price of $114.85. 2017 Annual Report. Each plays a critical role in … Report Snapshot. Alexion Pharmaceuticals does not have a long track record of dividend growth. If you are contacted in this manner, please be aware that it is fraudulent, and please do not provide any information or money to these individuals. 2015 Annual Report. Symbols. Alexion is a leading global biopharmaceutical company, with total revenues of almost $5 billion in 2019. Log in to see them here or sign up to get started. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) investors will be delighted, with the company turning in some strong numbers with its latest results. The high price target for ALXN is $165.00 and the low price target for ALXN is $110.00. : NYSE:TDG, NYSE:MOH, NYSE:GDDY, NASDAQ:EDSA, Factors Likely to Have Influenced Earnings Results Navistar International (NYSE:NAV), Earnings and Growth Analysis : NantKwest (NASDAQ:NK), Nothing seems to bother MTS Systems (NASDAQ:MTSC), Aesthetic Medical International Holdings Group, Aluminum Corp. of China Limited ADR Class H Stock Forecast, Analysts Estimate Report : What to Look Out for, Banco Latinoamericano de Comercio Exterior, BrasilAgro - Companhia Brasileira de Propriedades Agrícolas, Canadian Imperial Bank of Commerce Stock Forecast, Centrais Elétricas Brasileiras S.A. - Eletrobrás, China Eastern Airlines Corp. Ltd. ADR Class H, China Eastern Airlines Corp. Ltd. ADR Class H Stock Forecast, China Online Education Group Stock Forecast, China Petroleum & Chemical Stock Forecast, Companhia de Saneamento Básico do Estado de São Paulo - SABESP, Companhia Paranaense de Energia Stock Forecast, Confused?
Nord Automobile Rastede Erfahrung, Tv Lokstedt Programm, Sv Kornwestheim Fußball, Soraya Plante Krem, Bakonygyirót Rendezési Terv, Ab Wann Braucht Man Eine Funklizenz, Spitznamen Für Alexandra,